Aphria (TSX:APH) has completed its largest export of cannabis oil to date through a shipment to Australia’s Medlab Clinical (ASX:MDC), it announced on Thursday (July 26).

The record-breaking shipment comes as part of a prior agreement between the two companies, through which Aphria produces and supplies cannabis extracts. Medlab then uses the extracts in human trials to test pain management in oncology patients. For these clinical trials, Aphria provided both a high-CBD cannabis oil and a high-THC oil, both specifically designed for Medlab.


“Aphria is proud to support Medlab’s important and vital clinical research on the use of medical cannabis as an alternative treatment for pain management,” Vic Neufeld, Aphria CEO said in the statement.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“Medlab was our very first international partner, and as Aphria expands its operations around the globe, we will continue support the advancement of medical cannabis research through these valuable partnerships.”

Upon arrival at Medlab, the products shipped by Aphria are combined with the company’s medicine delivery system NanoCelle. Medlab is working towards finding an effective pain therapy method that targets advanced cancer pains through cannabis as opposed to opioids.

“Trial design, implementation and management is critical to developing a new, accepted drug – the work we are undertaking is to expand the medical toolkit especially with regards to current usage of opioids in patients with intractable pain,” Dr. Sean Hall, Medlab CEO said in a statement.

Aphria also has a shipment agreement in place with fellow Australian partner Althea Company, where Aphria provides cannabis oil and dried flower product for Australia’s medical cannabis market. The first shipment happened in late April of this year.

Shares of Aphria increased 0.09 percent on Thursday to close the trading session at C$10.45. Analysis consensus on TipRanks currently ranks the company as a “Strong Buy” with all three analysts giving the company a “Buy” rating. Aphria has an average price target of C$23.58, with a high estimate of C$26.25 and a low of C$20.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the first quarter ended March 31, 2021 after market close on May 10, 2021 .

Management will host a conference call and audio webcast that evening at 5:00 p.m. ET consisting of prepared remarks followed by a question and answer session related to the Company’s operational and financial highlights.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two new stores, the Company’s 85 th and 86 th nationwide to commemorate the 50 th anniversary of 420, the holiday recognizing cannabis culture.

The new Florida dispensaries, the Company’s 80 th and 81 st in the state, located in Eustis and Palm Beach Gardens , further demonstrate Trulieve’s goal of ensuring direct, reliable access to medical cannabis across its home state.

Keep reading... Show less

CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) leverages on timely and methodical execution of its revenue generating plan. It operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (www.canbudcorp.com).

Keep reading... Show less

(TheNewswire)

Keep reading... Show less

Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products

Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.

Keep reading... Show less